Successful transitions from siloed financial systems require clinical operations, finance, and IT to collaboratively recognize interconnected process issues. This shared urgency and a willingness to abandon "we've always done it this way" mentalities are the true indicators of an organization's readiness for change.

Misalignment often isn't the product team's fault. It stems from organizations intentionally withholding business context, goals, and financial realities. This "shielding" prevents PMs from connecting their work to the company's actual strategic objectives and mode of operation.

Trust should be the assumed baseline for any partnership, not a goal to be discussed. The more actionable focus is on transparency—the open, honest communication about both successes and failures. Transparency is how you navigate the real-world complexities and daily challenges of working together to solve customer problems.

The inefficiencies in partner programs, like slow MDF payments, are not due to untrustworthy people but a legacy Web2 system. As partner ecosystems scale globally, this centralized infrastructure creates more gatekeepers, rules, and checks, resulting in "bureaucracy at scale" that damages the partner experience.

The industry's standard practice of selecting sites based on pre-existing relationships and convenience—the "easy button"—is a primary driver of failure. This leads to 80% of activated sites missing enrollment targets and 30% enrolling zero patients, a massive, systemic inefficiency that data-driven approaches can solve.

For Ipsen, aligning with a partner on data-driven success criteria is not a post-deal task but a prerequisite for signing. If the parties cannot agree upfront on what defines success for a program, they will not proceed with the partnership, ensuring discipline and preventing future misalignments.

Successful, long-term vendor relationships are built on cultural alignment and a shared vision, not the lowest bid. Intensive due diligence should focus on finding a partner who is transparent, trustworthy, and willing to innovate and grow with your organization. A mismatched culture will lead to revisiting the selection process within a year.

For smaller biotechs, the key to a successful CRO relationship is treating them as a genuine partner. This requires moving beyond a transactional, fear-based dynamic to one of open communication and mutual respect. Biotechs should actively solicit CRO feedback, as they possess valuable cross-industry insights and can identify sponsor-side behaviors that need to change.

Using disconnected financial systems for modern, complex trials technically works but leads to crashes, slowness, and constant troubleshooting. This unsustainability directly risks study performance, site success, and patient engagement, making modernization a necessity, not a choice.